Adaptive lineage plasticity drives multidrug resistance to KRAS-EGFR targeted therapy
Drug Resistance Updates · 2026-09 · 88 · 101407
DOI: 10.1016/j.drup.2026.101407 ↗Kurz gefasst
Editorial in der Zeitschrift Drug Resistance Updates, 2026-09. Verfasst von Jianyou Gu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hepatopancreatobiliary Surgery, Chongqing General Hospital, School of Medicine, Chongqing University, Chongqing 401147, China. Die Arbeit nennt 9 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Graduate Scientific Research and Innovation Foundation of Chongqing.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Institute of Hepatopancreatobiliary Surgery, Chongqing General Hospital, School of Medicine, Chongqing University, Chongqing 401147, China.
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA. Electronic address: chenz@stjohns.edu.
Förderung
- National Natural Science Foundation of China
- Graduate Scientific Research and Innovation Foundation of Chongqing
Zitieren
APA
Gu, J., & Chen, Z. S. (2026). Adaptive lineage plasticity drives multidrug resistance to KRAS-EGFR targeted therapy. Drug Resistance Updates, 88, 101407. https://doi.org/10.1016/j.drup.2026.101407
Vancouver
Gu J, Chen ZS. Adaptive lineage plasticity drives multidrug resistance to KRAS-EGFR targeted therapy. Drug Resistance Updates. 2026;88:101407. doi:10.1016/j.drup.2026.101407
BibTeX
@article{Gu2026,
author = {Gu, Jianyou and Chen, Zhe-Sheng},
title = {Adaptive lineage plasticity drives multidrug resistance to KRAS-EGFR targeted therapy},
journal = {Drug Resistance Updates},
year = {2026},
volume = {88},
pages = {101407},
doi = {10.1016/j.drup.2026.101407}
}
EUVIMED